Health, Research, Science, Society

Is commuting harming our health?

COMMUTING

Intro: Some 4 billion people are known to travel between home and work, school, or college. Is the daily commute just something people love to hate, or a major health hazard?

SOME FORM OF COMMUTING has been part of our daily lives since the Neolithic age, and although many complain about their journeys, research shows that we wouldn’t want it any other way. We’re generally happiest when we have at least some distance between where we sleep and relax, and where we spend the bulk of our day. However, there are limits. People perceive their commute as part of their job, but if it makes us unhappy, we’re more likely to quit – so much so that an extra 20 minutes’ commuting time can reduce job satisfaction by the same amount as a 20 per cent pay cut.

Length of journey is the major factor in commuting: in the morning, your body clock is winding up the brain and body – alertness and attention increases with each passing minute, and if you’re stuck in traffic or a broken-down train during this precious primetime, then the most productive part of your day could be lost in transit. A morning journey of 45 minutes or more seems to be the tipping point at which the journey length starts to take a toll on physical and mental health. Workers who travel over 90 minutes each day are less fit, weigh more, and have higher blood pressure, compared to those with a shorter travel time. Longer commutes are also linked to health issues such as sleep problems, exhaustion, aches and pains, and overeating. Moreover, unpredictable and stressful delays, the chances of which increase the longer your commute, make the biggest negative impact on our health.

The method of travel also plays a part in how healthy your commute is. Driving takes the cake as the most stressful and unhealthiest way to commute. Public transport always comes out better, but simply using your legs to get to work – be it walking, cycling, or jogging – beats both.

Scientists have shown that a “good” commute is one that is long enough to give us time to draw a psychological line between homelife and work – but not so long that it makes us anxious, bored, or tired. Even if you work from home, you can benefit from a “virtual” commute by going for a short walk, run, or cycle to mark the start and end of your working day.

Research suggests that 15 minutes is the optimum length of time for a commute.

Want To Improve Your Commute?

. WALK, JOG, OR CYCLE – moving under your own power releases mood-lifting hormones and increases blood flow to the brain, making you happier and more productive.

. SIMPLIFY JOURNEYS that involve more than one stop; for example taking children to school on the way to work. Multiple-stage trips are the most stressful.

. PLAN YOUR DAY and spend the time mentally adjusting to work mode on the way in, and winding down on the journey home.

. FIND A NEW JOB if your commute is more than 90 minutes long – your health is probably suffering!

Standard
Britain, Government, Health, Medical, Society

One of Britain’s top medics says we need an NHS fit for the modern age

NATIONAL HEALTH SERVICE

PROFESSOR Stephen Smith, Dean of Medicine at Imperial College London, has been making his professional views known on the state of the NHS. The leading medic says that the service will never improve until the entire system has had radical surgery. In a brilliantly argued prognosis, Professor Smith has seen first-hand how the rest of the world almost always delivers better health care and says it is not about the money.

As a consultant gynaecologist and professor, he once advocated a change in the appointments system at one of the best hospitals in the country – the Rosie Hospital which is part of Addenbrooke’s in Cambridge.

The existing arrangements saw one batch of women called in at 9am, another at 11.30am. The medic became increasingly tired of seeing these patients sitting in the waiting area, often agitated and fed up.

He cites a woman who comes through the door having been made to wait for more than two hours and who is understandably angry, tired and resentful, especially as she’d been trying to entertain a screaming three-year-old. The clinician says you’re not going to get the best account of someone’s medical history in those circumstances.

He thought individual appointment times would be better: say, one every 15 minutes. Every doctor and patient he spoke to agreed.

You would think it easy to get things done for someone who is a professor in the NHS. Senior doctors are revered: their opinion and judgements count. But try to actually change anything and it’s a different story.

Naively, Professor Smith thought the switch to a 15-minute appointment system would be easy. Instead, he had to argue his case in front of at least six committees who each have a separate chairman and differing agendas.

That instance was just the first of many of his battles with the staggering bureaucracy within the NHS.

Next, his unit pioneered a scheme whereby pregnant women would carry their own medical records to appointments instead of looking up their records on the central database. The opposition to this was ferocious.

TWO

PROFESSOR SMITH’S unit pointed out that 17 per cent of central records could not be found. And once women were trusted with their own notes, only 5 per cent turned up without them.

He also mentions another arduous battle in which post-appointment letters are sent to the patient, with a copy to their GP – instead of the other way round.

At the heart of this chaos, he says, is a system that doesn’t put the patient first. The hurdles placed in the way of reform are designed to shore up the NHS – and are not in the best interests of the people who need it.

After Cambridge, Professor Smith became Dean of Medicine at Imperial College London, then CEO of the Imperial College Healthcare NHS Trust. He has also worked in Singapore and Australia.

Having had a view of our healthcare system from many perspectives, today’s NHS, he says, is simply not fit for purpose.

The additional funds the Government is about to direct to the NHS – some £36 billion over three years thanks to a new “Health and Social Care Levy”, including £5.4 billion to help clear the backlog caused by Covid – is well intentioned. But throwing money at the current system won’t get us anywhere.

We have been furnished with yet more stark reminders of the eye-watering sums the NHS is capable of wasting. It reportedly paid around £400 million a month last summer to block-book private hospital care for non-Covid patients.

A good idea, many might think. But astonishingly two-thirds of that went unused, perhaps for ideological reasons. Many NHS staff have an aversion to private medicine.

Meanwhile, waiting lists have grown. About 5.6 million people are waiting for hospital treatment, and that number looks set to double in the coming years.

Some £9 million of the new money is already earmarked for salaries of up to £270,000 for executives who will be expected to “actively champion diversity, inclusion and equality of opportunity”.

The medic says he has no quarrel with high salaries if they help to attract highly competent people. These are, after all, important jobs. When Professor Smith was chief executive at Imperial College, he was responsible for a £1.2 billion-a-year budget and had people’s lives at stake.

His prognosis says it’s time we had a major review of the way we run our health service. The NHS was born from such a review: the famous 1942 Beveridge Report, which looked at health care, social care and education. It was marvellous and set up an NHS that was suited to life 80 years ago.

We need now to set up a new Beveridge review. A national debate should be had about how to best fund and run our health service for the 21st century.

The review could be a Royal Commission, it could be an inquiry led by a judge. But, he says, any inquiry should typically involve medical personnel, economists, social-care experts, politicians, and patients, while avoiding childish, political squabbles. And we need to ask: what do we want, and how do we pay for it?

Professor Smith’s analysis says there are other, far better ways in which we can pay for healthcare in this country. The best would be the social insurance schemes seen elsewhere in the developed world – which would offer a vastly superior service than the one we have now.

The biggest obstacle to bringing in social insurance is actually the English language. When you mention social insurance, people in Britain almost freeze. They think: “I can’t afford medical insurance!”

But it’s not at all like private medical insurance – that’s completely misleading.

Under a social insurance scheme, the Government “hypothecates” – that is, promises – the money to go on healthcare. The scheme is then run-on insurance principles, but it’s paid for by the state out of taxation. And the money cannot be used for anything else.

Be wary of the objections from the Department of Health and the Treasury that social insurance is complicated and difficult to manage. We know through international comparisons that it provides a high standard of care – often higher than the NHS.

Many will have been cheered to see that the levy the prime minister announced last week will be hypothecated for health and social care. That’s a small step towards a proper system of social insurance.

THREE

THIS has nothing to do with “privatising” the health service, nor is it a criticism of our health professionals who have shown – especially over the past two years – selfless dedication. It is about dramatically improving healthcare in this country.

The great myth about the NHS is the belief that, because it provides for everyone, it is exceptional. But do people here seriously think the citizens of Belgium, Holland, Germany, New Zealand, Australia, Canada, Sweden, Switzerland, Denmark, Norway, Spain and Italy all go around worrying about whether they will get treatment for any condition they may have? Of course not.

All these countries have slightly different systems, so our NHS review could look at the right mix of options, taking ideas from several countries, perhaps, to get the best for the UK. 

Professor Smith highlights the Dutch system, which has a small number of sickness funds which patients can switch between without penalty.

As a nation, the medic says, we’ve set the bar far too low: grateful to see a GP after several weeks’ wait, grateful to have surgery, if only after the millions ahead of us on the waiting list have had theirs.

The truth is, he insists, is that we can do better.

Explaining that when he was a young doctor, the clinician was filled with fervour for the NHS. He had the fiercest arguments, insisting our system was the best in the world. Then he began travelling to other countries as part of his academic research into menstrual dysfunction.

Much of his early research was done in Sweden. That was his first eye-opener: the Swedish system was outstanding.

One of the first things that impressed him was that consultants went outside their hospitals and held clinics in GP surgeries.

That was enlightening and certainly new to him. In Sweden, the consultant was expected to go to the patient, not the other way round. That is still a feature of Swedish medicine and we should look at it closely.

Right now, too much in healthcare isn’t right for the patient but persists because “we’ve always done it this way”.

And as for privatisation? When people talk of “mixing public with private”, there’s a widespread suspicion that evil American corporations will descend and make huge profits from “our” precious NHS.

But – and here’s the key point – large parts of the NHS are already private.

In the many years of working in hospitals, Professor Smith has never understood why so many people haven’t realised that GPs don’t actually work for the health service. They are small businesses. So are dentists, including those offering NHS care.

The first criticism from the Left is always, “Look at the American system!”

Professor Smith acknowledges that the American system is atrocious – not to mention terrible value for money. Many people live in fear of not being able to pay their medical bills and care costs twice as much as anywhere else in the world. Nobody wants that. What would improve Britain’s healthcare is a system like those of many of our European neighbours.

The biggest challenge for the UK health service now is how to integrate primary care (GPs, dentists and opticians) with secondary care (including hospitals). This comes naturally in a less “top-down” social-insurance system.

FOUR

SOCIAL CARE has long been neglected, but it is key to making the whole system work. It’s about getting older and vulnerable people home from hospital, rather than leaving them stuck there when they no longer need to be.

If Mrs Jones, 95, is ready to be discharged but social care can’t ensure she will be looked after at home, she must stay in hospital. Then the bed she would have vacated is not available for the next person needing an operation, and so on…

Lack of integration in the NHS is systemic: most patients are astonished, the professor says, at the difficulty of sharing records between a hospital and general practice.

The clinician says that if you are assessing someone’s health needs, you should be able, with their consent, to access their primary care records, operation notes and anything else that is relevant. But this is very difficult – although technology is slowly improving matters.

Professor Smith poses a final question. Should we now change the role of GPs to focus more on long-term care?

The medic says that if you are a woman with problem periods, say, why shouldn’t you access an app, put in your medical history and refer yourself to a consultant whose team will be able to look at the problem and decide if you need to come and see them? Why should your GP be the only port of call?

This final point brings Professor Smith back to his key point. The NHS as we have it was designed for life 80 years ago, when your GP was the person – invariably a man, in those days – who acted as a gatekeeper.

That was then, he says. What we need now is an NHS for the current and modern era.

Standard
Health, Medical, Research

New Alzheimer’s drug offers hope to sufferers

DEMENTIA/ALZHEIMER’S DISEASE

THE first new pharmaceutical drug for Alzheimer’s in almost two decades has won approval in the United States – raising hopes that the drug could soon be used in the UK.

Aducanumab targets the cause of the disease rather than its symptoms.

Medical and health charities have welcomed the announcement, describing its approval as a “major milestone” for the millions of people living with dementia. But scientists are divided because of the uncertainty over trial results.

The US Food and Drug Administration said there was “substantial evidence that aducanumab reduces amyloid beta plaques”. Amyloid is a protein that forms clumps in the brain that can damage cells and trigger dementia. Aducanumab works by sticking to these clumps and removing them.

However, late-stage international trials of the treatment in 2019, involving about 3,000 patients, were halted when analysis showed the drug was no better at slowing the deterioration of memory than a placebo. Following further analysis, manufacturer Biogen said the drug did work and significantly slowed cognitive decline if given in higher doses.

Biogen have not released the cost of the treatment, but analysts estimate it could cost up to £35,000 a year. Tens of thousands of Britons with a mild form of the disease could be suitable for the drug if it were to be approved here.

Professor Bart De Strooper, director the UK Dementia Research Institute, said: “With no effective therapies currently available to modify the progression of this devastating condition, this is a major milestone for the millions of people living with Alzheimer’s. However, I fear the controversy and uncertainty surrounding the trials will limit the impact of this new treatment for the disease.”

A spokesperson for the research department at the Alzheimer’s Society, said: “It’s promising to see that aducanumab has been approved for use in people with early-stage Alzheimer’s disease – the first drug to be approved in nearly 20 years by the US regulatory authorities.

“We await the opinion of the European Medicines Agency and the outcome of any application made to the UK regulatory authorities, to give clarity to people with early Alzheimer’s disease in the UK. Whatever the outcome of their decision, this is just the beginning of the road to new treatments for Alzheimer’s disease.”

Another health charity, Alzheimer’s Research UK, said it had written to UK Health Secretary Matt Hancock asking the Government to prioritise the fast-track approval process for the drug in the UK.

Its chief executive, Hilary Evans, said: “People with dementia and their families have been waiting far too long for life-changing new treatments.”

Standard